A Professor of applied health technology at Blekinge Institute of Technology recently confirmed a Lyme disease vaccine candidate is being tested in Sweden.
Johan Sanmartin Berglund leads the Swedish part of phase 3 clinical study evaluating VLA15, a multivalent recombinant protein vaccine candidate targeting the outer surface protein A of Borrelia.
This innovative vaccine is designed for prophylactic, active immunization to protect people against most human pathogenic Borrelia species.
-
-
COVID-19 Pandemic Challenges Osteoporosis Management
-
AstraZeneca, J&J Resume U.S. COVID-19 Vaccine Trials
-
Survival From COVID-19 High in Patients With Psoriasis
-
FDA Needs More Safety Data on COVID-19 Vaccines, Experts Say
